Munich, Germany – September 2026 — The biopharmaceutical industry is navigating a changing deal environment, with companies reassessing pipelines, seeking external innovation and exploring new sources of capital and strategic growth. Against this backdrop, BioPharma Deals 2026 will take place on 24–25 November 2026 in Munich, Germany.
The conference will bring together senior professionals involved in business development, licensing, corporate development, investment, mergers and acquisitions, and strategic partnerships. Its focus is on the commercial opportunities shaping the biopharma sector and the relationships required to advance them.
The conference will address key areas of deal activity, including licensing and partnering, M&A, co-development, investment, due diligence, valuation and strategic transactions. Industry leaders will share perspectives on current market dynamics, while participants will have opportunities to discuss potential collaborations and investment prospects.
A central element of the conference is its structured one-to-one partnering programme, with more than 500 meetings expected across the two-day event. These meetings are designed to facilitate direct discussions between companies with complementary interests, from emerging biotechs seeking strategic partners to established pharmaceutical organisations evaluating new opportunities.
The event will also provide a meeting point for pharmaceutical and biotechnology companies, investors, advisors and other professionals active in the life sciences transaction ecosystem. Participants can use the platform to identify potential partners, evaluate opportunities and develop relationships that extend beyond the conference.
A Closer Look at the Deal Environment
The current biopharma market is placing greater emphasis on selectivity and strategic alignment. Companies are evaluating external opportunities against increasingly specific pipeline priorities, commercial objectives and development strategies. This is influencing how organisations approach licensing discussions, asset acquisitions and collaborative development.
For biotech companies, presenting a compelling opportunity now requires more than demonstrating scientific potential. Clear development plans, differentiated positioning, realistic commercial assumptions and an understanding of prospective partners can play an important role in attracting interest. For pharmaceutical companies, the challenge lies in identifying opportunities that complement existing capabilities while offering a credible path to long-term value creation.
These considerations are also changing the role of business development teams. Rather than operating solely around individual transactions, deal professionals are increasingly involved in broader portfolio strategy, market intelligence and relationship development. Understanding where a potential partner is heading can be just as important as assessing what it can offer today.
With the industry continuing to evolve, effective dealmaking increasingly depends on informed decision-making, clear strategic objectives and strong counterpart relationships. BioPharma Deals 2026 will provide a dedicated setting for professionals to examine these priorities and pursue opportunities across the biopharma value chain.
For Further information about the conference, agenda, participation opportunities, and registration please visit:
https://www.biopharmadeals.com
Contact Person:
Kelly Rose
Email: kelly@biopharmadeals.com
